Blue Cross complete of Michigan

Suite 1300
4000 Town Center
Southfield, MI 48075

mibluecrosscomplete.com

Provider Alert

To: All Blue Cross Complete providers

Date: Oct. 31, 2025

Subject: CDC recommends new injectable HIV prevention drug

The Centers for Disease Control and Prevention released new clinical guidance formally recommending the twice-a-year injectable lenacapavir as an additional option for HIV prevention in the United States. The U.S. Food and Drug Administration approved lenacapavir for HIV pre-exposure prophylaxis, or PrEP in June 2025.

This is a significant step forward in expanding prevention options and reflects decades of research, partnership, and commitment to ending the HIV epidemic, according to the Michigan Department of Health and Human Services.

The Clinical Recommendations for lenacapavir are an addition to the CDC's current Clinical Guidance for PrEP, which includes daily oral pills or injectable cabotegravir, which is administered every two months. All FDA-approved PrEP options are highly effective in preventing HIV when taken as prescribed.

Health care providers are encouraged to inform all sexually active adults and adolescents about proven options for PrEP and prescribe PrEP to anyone who requests it.

If you have any questions, contact your Blue Cross Complete provider account executive or Provider Inquiry at 1-888-312-5713.

Our website is **mibluecrosscomplete.com. While website addresses for other organizations are provided for reference, Blue Cross Complete doesn't control these sites and isn't responsible for their content.*

Blue Cross Complete of Michigan LLC is an independent licensee of the Blue Cross and Blue Shield Association.